• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Live attenuated measles virus
    2 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Priorix
    GSK
    RX
    partial basket chart
    Multiple ingredients
    Priorix

    MMR Vaccine. Live attenuated measles virus 10^3.0 CCID50, Live attenuated mumps virus 10^3.7 CCID50, Live attenuated rubella virus 10^3.0 CCID50.
    VIALS (+ sterile diluent): 1 x 0.5 ml.
    Single dose S.C.
    Active immun. against measles, mumps.
    rubella.
    C/I: Hypersens. to the act. subst. or to
    neomycin. Hist. of contact dermatit. to
    neomycin is not a contraindic. For
    hypersens. reactions to egg proteins.
    See lit. Severe humoral / cellular (prim./
    acquired) immunodefic., e.g. severe
    combined immunodefic.,
    agammaglobulinemia and AIDS or
    sympt. HIV infect. or an age-specific
    CD4+ T-lymphocyte percentage in child.
    below 12 mnths.: CD4+ <25%; child.
    btwn. 12-35 mnths.: CD4+ < 20%; child.
    btwn .36-59 mnths.: CD4+ < 15% .
    Preg., preg. should be avoided for 1 m
    follow. vaccin. Pts. with acute sev. febrile
    illness.

    Priorix-Tetra
    GSK
    RX
    not in the basket chart
    Multiple ingredients
    Priorix-Tetra

    MMRV Vaccine. Live attenuated measles virus NLT 10^ 3 CCID, Live attenuated mumps virus NLT 10^ 4.4 CCID, Live attenuated rubella virus NLT 10^ 3 CCID, Varicella virus live attenuated >=10 ^ 3.3 PFU.
    AMP. (Pwdr. + solv. for sol. for inj.): 1, 10,
    20, 50×0.5ml. Infan., child. 12 mnths.
    up to 12 yrs.: two doses (each of 0.5
    ml). The interv. should prefer. btwn. 6
    wks.- 3 mnths. When the 1st dose is admin. at 11 mnths. of age, the 2nd
    dose should be admin. within 3 mnths.
    Under no circumst. should the dose
    interv. be less than 4 wks.
    Child. 9-11 months: In case an
    epidemiological situation requires
    vaccinating infants less than 12
    months of age, the first dose can be
    given as from 9 months of age. A 2nd
    dose should be given three months
    after the 1st dose. See lit.
    Active immunis. against measles,
    mumps, rubella, varicella in child. 12
    mnth. - 12 yrs. includ. Use in infants 9-11
    mnths. could be consid. under special
    circumst.
    C/I: Pts. acute sev. febr. illness.
    Hypersens. to act. subst. or to neomycin.
    Previous episodes of hypersens. after
    admin. of MMR and/or varicella vacc.
    Severe humoral/ cellular (primary/
    acquired) immunodefic., e.g. severe
    combined immunodef.,
    agammaglobulinemia, AIDS or sympt.
    HIV infec. or an age-specific CD4+
    T-lymphocyte percentage in child.
    below 12 mnths.: CD4+ <25%; children
    btwn. 12-35 mnths.: CD4+ < 20%; child.
    btwn. 36-59 mnths.: CD4+ < 15%
    Preg., preg. should be avoid. for 1m.
    follow. vacc.

    CLOSE